Tiotropium Respimat®vs.HandiHaler®: real-life usage and TIOSPIR trial generalizability-Reference-Cited by-同舟云学术

Tiotropium Respimat®vs.HandiHaler®: real-life usage and TIOSPIR trial generalizability

Published:2015-12-23 Issue:2 Volume:81 Page:379-388
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Schmiedl Sven¹²,Fischer Rainald³,Ibanez Luisa⁴⁵,Fortuny Joan⁶,Thürmann Petra¹²,Ballarin Elena⁴,Ferrer Pili⁴,Sabaté Monica⁴,Rottenkolber Dominik⁷⁸,Gerlach Roman⁹,Tauscher Martin⁹,Reynolds Robert¹⁰,Hasford Joerg¹¹,Rottenkolber Marietta¹¹

Affiliation:

1. Department of Clinical Pharmacology, School of Medicine, Faculty of Health; Witten/Herdecke University; Witten Germany

2. Philipp Klee-Institute for Clinical Pharmacology; HELIOS Clinic Wuppertal; Wuppertal Germany

3. Pneumologische Praxis Muenchen - Pasing; Munich Germany

4. Fundació Institut Català de Farmacologia; Hospital Universitari Vall d'Hebron; Barcelona Spain

5. Departament de Farmacologia, Terapèutica i Toxicologia; Universitat Autònoma de Barcelona; Barcelona Spain

6. Novartis Farmaceutica S.A.; Barcelona Spain

7. Institute of Health Economics and Management; Ludwig-Maximilians-Universitaet Muenchen; Munich Germany

8. Helmholtz Zentrum Muenchen - German Research Center for Environmental Health; Member of the German Center for Lung Research; Neuherberg Germany

9. National Association of Statutory Health Insurance Physicians of Bavaria; Munich Germany

10. Pfizer; New York NY USA

11. Institute for Medical Information Sciences, Biometry, and Epidemiology; Ludwig-Maximilians-Universitaet Muenchen; Munich Germany

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.12808/fullpdf

Reference35 articles.

1. Global Initiative for Chronic Obstructive Lung disease (GOLD) 2014 http://www.goldcopd.org

2. On comparing different devices of inhalation products;Garcia;Respir Med,2009

3. The efficacy of tiotropium administered via Respimat Soft Mist inhaler or HandiHaler in COPD patients;Noord;Respir Med,2009

4. Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease;Hohlfeld;J Clin Pharmacol,2014

5. Use of tiotropium Respimat Soft Mist inhaler versus HandiHaler and mortality in patients with COPD;Verhamme;Eur Respir J,2013

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Overview of Recently Published Patents on Pulmonary Drug Delivery Devices;Recent Advances in Drug Delivery and Formulation;2023-06

2. Risk Assessment of Acute Myocardial Infarction and Stroke Associated with Long-Acting Muscarinic Antagonists, Alone or in Combination, versus Long-Acting beta2-Agonists;International Journal of Chronic Obstructive Pulmonary Disease;2022-08

3. Efficacy and cardiovascular safety of LAMA in patients with COPD: a systematic review and meta-analysis;Journal of Investigative Medicine;2021-08-06

Healthcare Resource Utilization, Exacerbations, and Readmissions Among Medicare Patients with Chronic Obstructive Pulmonary Disease After Long-Acting Muscarinic Antagonist Therapy Initiation with Soft Mist versus Dry Powder Inhalers

;International Journal of Chronic Obstructive Pulmonary Disease;2020-12

5. The Respimat® Soft Mist Inhaler: Implications of Drug Delivery Characteristics for Patients;Clinical Drug Investigation;2019-08-03